[Relationship between antihypertensive drug use and development of atrial fibrillation in hypertensive patients in a Primary Care center].
BACKGROUND
Although antihypertensive treatment can reduce the risk of cardiovascular morbimortality, studies aimed at evaluating the association between antihypertensive drug use and incidence of atrial fibrillation (AF) yield mixed results. This study aimed to determine the possible relationship between antihypertensive drug use and development of AF.


METHODS
Case control study.


METHODS
Hypertensive patients with AF diagnosed at least one year after the start of drug treatment for hypertension.


METHODS
Hypertensive patients without AF with pharmacological antihypertensive treatment for at least one year, matching by sex, age and duration of antihypertensive therapy at diagnosis of AF cases. The study included 136 cases and 132 controls.


METHODS
AF, antihypertensive drugs, control of hypertension, duration of treatment with antihypertensive drugs, number of antihypertensive drugs.


METHODS
Crude OR were calculated, with logistic regression being used to calculate the adjusted odds ratios.


RESULTS
Overall, diuretics was close to statistical significance: OR 0.616 (95% CI 0.365 to 1.040), as a protective factor for development of AF. Calcium channel blockers behaved as a protective factor against development of AF at 75 years or older (OR 0.366; 95% CI 0.173 to 0.772), and within this age in women (OR 0.343; 95% CI 0.145-0.811).


CONCLUSIONS
Calcium channel blockers in the group of 75 years or more, especially in women, worked statistically significant as a drug protecting against the appearance of AF. Diuretics may have a protective role in AF incidence in all hypertensive patients.
Unidad de Gestión Clínica, Centro de Salud Puerto Real, Distrito de Atención Primaria Cádiz, Bahía, La Janda, Servicio Andaluz de Salud, Puerto Real, Cádiz, España.
A Á
AÁ
Mena-Villalba
Unidad de Gestión Clínica, Centro de Salud Puerto Real, Distrito de Atención Primaria Cádiz, Bahía, La Janda, Servicio Andaluz de Salud, Puerto Real, Cádiz, España. Electronic address: jlendinezd@hotmail.com.
J M
JM
Lendínez-de la Cruz
Unidad de Gestión Clínica, Centro de Salud Puerto Real, Distrito de Atención Primaria Cádiz, Bahía, La Janda, Servicio Andaluz de Salud, Puerto Real, Cádiz, España.
C M
CM
Cubero-Gómez
Unidad de Gestión Clínica, Centro de Salud Puerto Real, Distrito de Atención Primaria Cádiz, Bahía, La Janda, Servicio Andaluz de Salud, Puerto Real, Cádiz, España.
M
M
Monsalvo-Moro
Unidad de Gestión Clínica, Centro de Salud Puerto Real, Distrito de Atención Primaria Cádiz, Bahía, La Janda, Servicio Andaluz de Salud, Puerto Real, Cádiz, España.
R C
RC
Gutiérrez-Ruíz
Unidad de Gestión Clínica, Centro de Salud Puerto Real, Distrito de Atención Primaria Cádiz, Bahía, La Janda, Servicio Andaluz de Salud, Puerto Real, Cádiz, España.
A
A
García-Alfonsín
D000367:Age Factors; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000453:epidemiology / Q000517:prevention & control*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D016022:Case-Control Studies; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000628:therapy*; D015994:Incidence; D016015:Logistic Models; D008297:Male; D011320:Primary Health Care; D012737:Sex Factors
D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics
Antihypertensive drug; Atrial fibrillation; Fibrilación auricular; Fármacos antihipertensivos; High blood pressure; Hipertensión arterial